
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is financially sound, with a strong focus on developing and advancing one-time gene therapies tailored to treat neurodegenerative diseases. The company's pipeline, with its lead candidate PBFT02, shows promise for addressing critical underlying pathologies and has the potential for significant revenue growth. With the projected 5x multiple to peak sales and a reasonable discount rate, Passage Bio's stock has the potential for positive returns for investors in the long term.
Bears say
Passage Bio is in a difficult position, with regulatory uncertainties and challenges in conducting clinical trials for their lead program PBFT02, leading to a downgrade from Outperform to Neutral for the stock. This is further exacerbated by the company's limited cash runway and competition in the indications they are pursuing. While the biomarker data from their upliFT-D study shows potential for clinical benefit, the lack of flexibility from the FDA and the significant resources and time needed for a randomized controlled study make success for Passage Bio's programs uncertain.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares